Key Highlights
- Intensity Therapeutics restarted patient dosing in its breast cancer trial in July 2026 after a 10-month pause for skin irritation, and began reopening US sites in its Phase 3 sarcoma trial that had been paused for funding reasons.
- Cash stood at $9.5 million against roughly $3 million of quarterly operating spending, insufficient to fund both a Phase 3 survival trial and a Phase 2 study to completion without additional financing.
- Early data from 14 breast cancer patients before the pause showed 71% achieving pathological complete response with INT230-6 versus 42% for standard care alone, though the sample is too small to draw firm conclusions.
Intensity Therapeutics, Inc. (NASDAQ:INTS) spent much of the past 18 months with both of its lead cancer studies standing still. One was halted for money, the other for safety. In July it began dosing patients again in the smaller of the two, and on 11 August put financial detail behind that restart.
The clinical-stage biotech is built around one asset, INT230-6, a drug injected directly into a solid tumour rather than infused into the blood. It pairs two established chemotherapies, cisplatin and vinblastine sulfate, with a diffusion-enhancer molecule that spreads them through the tumour while keeping them largely local.
The arithmetic is tight: $9.5 million of cash at 30 June against roughly $3 million of quarterly operating spending, and a Market Value of about $11 million to $13 million after a 1-for-25 reverse share split in February.
What Happened
On 15 July 2026 Intensity restarted patient treatment in INVINCIBLE-4, a randomised, open-label Phase 2 study in presurgical triple-negative breast cancer. Dosing resumed in Switzerland, and the first French site opened in August.
The study had been paused in September 2025 after skin irritation appeared in the cohort receiving INT230-6. In March 2026 it filed a protocol amendment with Swissmedic, the Swiss medicines regulator, and the Swiss ethics committee, lowering the ratio of drug Volume to tumour volume and replacing two injections with one.
Work also began in April 2026 to reopen enrolment at a limited number of United States sites in INVINCIBLE-3, the Phase 3 soft tissue sarcoma trial, under an FDA-reviewed amended protocol. That study was paused in March 2025 for funding reasons, not safety, and European restart paperwork remains in progress.
Why It Matters
With both studies frozen, Intensity had no path to the data that determines its value. The pauses had different causes but the same consequence, and dosing again is the difference between a stalled asset and one accumulating evidence.
The trial's main measure is pathological complete response, or pCR: when the tumour is removed at surgery, pathologists find no remaining invasive cancer in the breast tissue or lymph nodes. In triple-negative disease it is a well-established marker of how patients fare afterwards. Intensity also said it held more than 20 partnering conversations at the BIO 2026 conference, and a partner funding development would change its position far more than anything it can do alone.
The Numbers
Second-quarter 2026 net loss was $3.0 million, wider than $2.5 million a year earlier. Research and Development rose to $1.8 million from $1.5 million and general and administrative costs to $1.3 million from $1.2 million, lifting operating expenses to $3.1 million from $2.7 million. Loss per share was $1.11 on a weighted average 2,706,607 shares; the six-month loss narrowed to $5.4 million from $5.9 million.
Cash stood at $9.5 million on 30 June, down from $11.9 million at the end of 2025. A $60 million at-the-market share Facility established in March 2026 raised $1.6 million net in the second quarter and $1.3 million net afterwards. During 2025 it raised more than $20 million gross and cut its annual net loss to $11.6 million from $16.3 million.
Clinically, 14 patients had been treated in INVINCIBLE-4 before the pause, seven per arm. Five of seven given INT230-6 with standard care achieved a pCR against two of six evaluable controls, framed by the company as roughly 71 percent versus 42 percent. The INT230-6 arm recorded 14 grade 3 or higher adverse events against 25 in the control arm. Roughly 47 further patients are planned. INVINCIBLE-3 had enrolled 21 patients and uses overall survival as its primary endpoint; more than 200 patients have received INT230-6 across completed studies.
What It Means for the Company
One overhang unrelated to science has cleared. Nasdaq granted a 180-day extension in December 2025 to fix a minimum bid price deficiency; the company announced a reverse split on 13 February 2026 at one share for every 25, effective 19 February, and confirmed compliance was regained on 6 March. It also said United States Patent 12,496,345 was granted in December 2025.
The core constraint is unchanged, and management has been candid: the second-quarter release said site activation and enrolment rates are expected to increase as sufficient funding is obtained, so the financing calendar sets the pace of both programmes. With a market value close to its cash balance, investors are assigning little to the pipeline.
Risks Investors Should Watch
Funding dominates. At roughly $3 million of quarterly operating expenses, $9.5 million does not fund a Phase 3 survival trial and a Phase 2 study to completion. The share facility is the likely near-term source of cash, and selling stock near $4 against a few million shares means dilution can be rapid.
The clinical evidence is early. Fourteen patients is a very small sample, the comparison was not designed to prove efficacy, and one control patient was not evaluated. The revised regimen has produced no results yet: the lower ratio and single injection may ease the skin irritation, but whether efficacy holds at lower exposure is untested.
Twenty-one patients into a Phase 3 survival trial is early on a long, expensive road, and the European restart depends on regulatory paperwork. Listing compliance has been restored, but shares traded as low as $3.51 over the past year. No Partnership has been signed.
What Comes Next
The nearest checkpoint is INVINCIBLE-3, where the company targeted activation of a limited number of United States sites during the third quarter of 2026. Confirmation that sites are open and screening would be the first proof the restart is real.
For INVINCIBLE-4, site activation across Switzerland and France continues, with enrolment targeted for completion by the end of 2027, and any safety readout on the revised single-injection regimen will be watched closely. Third-quarter results are due in the autumn and will show how heavily the share facility has been used.
Conclusion
Intensity Therapeutics has restarted both of its clinical programs after separate pauses, one for safety and one for money, which is a genuine step forward after 18 months of standing still. The early breast cancer data is encouraging, but it comes from just 14 patients under a regimen the company has since modified, meaning the revised single-injection protocol hasn't yet been tested for efficacy. The core problem from before the pause hasn't gone away: $9.5 million doesn't fund a Phase 3 survival trial and a Phase 2 study simultaneously, and management has been unusually direct that enrollment pace itself depends on obtaining sufficient funding, making the company's more than 20 partnering conversations at BIO 2026 as consequential to watch as any clinical readout.






Please wait processing your request...